ImmunityBio reported durable complete responses in an off‑the‑shelf CD19 CAR‑NK program for Waldenström’s macroglobulinemia, with responses sustained through seven and 15 months in the first patients. Company data show the regimen—delivered outpatient and combined with rituximab—achieved disease control without lymphodepletion in four treated patients. The early dataset comes from a small Phase 1 cohort and was presented by the company during conference week; investigators emphasized the potential to simplify cell therapy logistics by avoiding individualized manufacturing and lymphodepletion. These results derive from an ongoing QUILT‑style trial framework testing allogeneic CAR‑NK agents in relapsed/refractory B‑cell malignancies. The therapy’s outpatient dosing schedule and lack of lymphodepletion reduce barriers to delivery but require validation in larger cohorts. Investors reacted quickly to the readout, underscoring appetite for off‑the‑shelf cell approaches that can deliver rapid, clinic‑friendly dosing. Clinicians flagged the need for longer follow‑up and broader safety data, particularly on persistence and immune‑mediated adverse events. Additional enrollment and controlled cohorts will determine whether the early complete responses translate into durable survival benefits across a wider patient population.